名称：原装进口| Bortezomib, Free Base
Storage: Store at or below -20 ºC.
Solubility: Soluble in DMSO at 200 mg/mL; soluble in ethanol at 200 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-10 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A. Bortezomib, Free Base, 99%.
View the MSDS for this product
Bortezomib inhibits cell proliferation of H460 cells (Human non-small cell lung cancer cell lines) with an IC50 of 0.1 µM. Ling, Y., et al. Bortezomib is active in preclinical models of human prostate cancer, while its effects on apoptosis versus angiogenesis are cell type dependent.
"Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines." Clin. Cancer Res. 9: 1145-1154 (2003). In a study with the National Cancer Institutes panel of 60 human cell lines, bortezomib showed a mean IC50 of 7 nM as tested by SRB analysis.
NOTE: The bortezomib sold by LC Laboratories is NOT Velcade®, and is NOT for human use. Bortezomib caused comparable growth suppression in LNCaP-Pro5 and PC3M-Pro4 cells with an IC90 of 10 nM. Williams, S., et al. Bortezomib is the active ingredient in the drug sold under the trade name Velcade®.
This drug has been approved in at least one country to treat multiple myeloma. "Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts."